Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study

Sacchetti, Emilio; Galluzzo, Alessandro; Valsecchi, Paolo; Romeo, Fabio; Gorini, Barbara; Warrington, Lewis

doi:10.1016/j.schres.2009.05.002

Cited by 37 publications

(23 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present review found 2 RCTs comparing clozapine monotherapy with treatment with high-dose olanzapine52,53 and a further study examining treatment with ziprasidone with treatment-resistant participants 54. These studies will be discussed in detail below.…”

Section: Clozapine Monotherapymentioning

confidence: 97%

“…Sacchetti et al investigated the use of ziprasidone compared to clozapine over an 18-week period in acutely unwell people (mean PANSS total score ∼107) with a history of multiple refractoriness to antipsychotics using a double-blind design 54. Decreases in the PANSS score were similar in each group; clozapine −24.5 (95% CI −29.7 to −19.2) and ziprasidone −25.0 (95% CI −30.2 to −19.8).…”

Section: Options For Clozapine-intolerant or Clozapine-resistant Peoplementioning

confidence: 99%

See 1 more Smart Citation

Pharmacotherapy for treatment-resistant schizophrenia

McIlwain¹,

Harrison²,

Wheeler³

et al. 2011

NDT

View full text Add to dashboard Cite

Schizophrenia is a disabling mental illness with a lifetime prevalence of 0.7% worldwide and significant, often devastating, consequences on social and occupational functioning. A range of antipsychotic medications are available; however, suboptimal therapeutic response in terms of psychotic symptoms is common and affects up to one-third of people with schizophrenia. Negative symptoms are generally less amenable to treatment. Because of the consequences of inadequate symptom control, effective treatment strategies are required for people with treatment-resistant schizophrenia. Clozapine has been shown to be more effective than other antipsychotics in treatment-resistant populations in several studies; however, the occurrence of adverse effects, some of which are potentially life-threatening, are important limitations. In addition to those who are intolerant to clozapine, only 30% to 50% experience clinically significant symptom improvement. This review describes the recent evidence for treatment strategies for people not responding to nonclozapine antipsychotic agents and people not responding or only partially responding to clozapine.

show abstract

Section: Clozapine Monotherapymentioning

confidence: 97%

Section: Options For Clozapine-intolerant or Clozapine-resistant Peoplementioning

confidence: 99%

Pharmacotherapy for treatment-resistant schizophrenia

McIlwain¹,

Harrison²,

Wheeler³

et al. 2011

NDT

View full text Add to dashboard Cite

show abstract

“…Patients with schizophrenia often have glucose abnormalities and are overweight because of familial, possibly genetic susceptibility, intrinsic metabolic disadvantages, persistent unhealthy lifestyles, and contamination of antipsychotic medications (Wooten, 2007;Sacchetti et al, 2009). In turn, several independent lines of evidence support the hypothesis of schizophrenia as a neurodevelopmental disorder (Harrison, 2007).…”

mentioning

confidence: 99%

Polymorphic CA repeat in IGF-I gene: lack of association with schizophrenia

Bonvicini¹,

Gennarelli²,

Scassellati³

et al. 2010

Psychiatric Genetics

Self Cite

View full text Add to dashboard Cite

“…Todos ECRs constituíram-se em seguimento de grupos paralelos, 26 informaram que apenas 20,5% dos pacientes do grupo alocado para tratamento com ziprasidona foram intolerantes, e 11% do grupo alocado para tratamento com clozapina. Nenhum destes estudos apresentou dados em separado para a população de pacientes intolerantes.…”

Section: Desenhounclassified

“…26,163,228,231,235 Um estudo analisou os dados apenas dos pacientes que completaram o estudo. 230 Para os outros, não foi possível determinar como foi o manejo dos dados incompletos.…”

Section: Dados Incompletosunclassified

Eficácia de antipsicóticos atípicos comparados à clozapina em pacientes com esquizofrenia refratária: revisão sistemática e metanálise

Souza¹

View full text Add to dashboard Cite

AGRADECIMENTOSAos meus pais, Judite e Paulo, e à minha irmã, Jussimara, por terem colocado a educação como o valor central da minha vida, proporcionando as bases para a realização desta dissertação e de todos os outros projetos.À Mônica Kayo, colega, sócia, colaboradora e, acima de tudo, amiga, pelo apoio fundamental em todos os momentos.Ao meu orientador, Professor Helio Elkis, pelo estímulo e orientação que possibilitaram a realização desta dissertação.Aos Professores Ângelo Cunha, Hilda Gonçalves e Flávio Kapczinski, que, ainda na graduação, me incentivaram pelos caminhos da psiquiatria e da academia.Aos meus colegas, professores e amigos da psiquiatria da UNICAMP, pelo papel fundamental que tiveram na minha formação como psiquiatra, influenciando na realização deste projeto.Aos meus colegas e amigos do PROJESQ, pelo carinho sempre proporcionado.Aos meus colegas, chefes e amigos da Abbott Laboratórios, pela compreensão e apoio sempre demonstrados. À Carolina Rehem, profissional de informações médicas, pelo apoio fundamental na busca dos artigos.

show abstract

Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study

Abstract: ErratumErratum to "Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study"

Cited by 37 publications

References 62 publications

Pharmacotherapy for treatment-resistant schizophrenia

Pharmacotherapy for treatment-resistant schizophrenia

Polymorphic CA repeat in IGF-I gene: lack of association with schizophrenia

Eficácia de antipsicóticos atípicos comparados à clozapina em pacientes com esquizofrenia refratária: revisão sistemática e metanálise

Contact Info

Product

Resources

About